These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35696669)

  • 21. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
    Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
    Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer.
    He X; Jiang Y; Zhang L; Li Y; Hu X; Hua G; Cai S; Mo S; Peng J
    Front Bioeng Biotechnol; 2023; 11():1190637. PubMed ID: 37284236
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids.
    Mao Y; Wang W; Yang J; Zhou X; Lu Y; Gao J; Wang X; Wen L; Fu W; Tang F
    Protein Cell; 2024 Apr; 15(4):285-304. PubMed ID: 37345888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
    Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
    Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
    Mo S; Tang P; Luo W; Zhang L; Li Y; Hu X; Ma X; Chen Y; Bao Y; He X; Fu G; Xu X; Rao X; Li X; Guan R; Chen S; Deng Y; Lv T; Mu P; Zheng Q; Wang S; Liu F; Li Y; Sheng W; Huang D; Hu C; Gao J; Zhang Z; Cai S; Clevers H; Peng J; Hua G
    Adv Sci (Weinh); 2022 Nov; 9(31):e2204097. PubMed ID: 36058001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
    Usui T; Sakurai M; Umata K; Elbadawy M; Ohama T; Yamawaki H; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Sato K; Kaneda M; Sasaki K
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29642386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
    Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
    Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study.
    Wang T; Pan W; Zheng H; Zheng H; Wang Z; Li JJ; Deng C; Yan J
    Dis Colon Rectum; 2021 Jul; 64(7):833-850. PubMed ID: 33709991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
    Schmäche T; Fohgrub J; Klimova A; Laaber K; Drukewitz S; Merboth F; Hennig A; Seidlitz T; Herbst F; Baenke F; Ada AM; Groß T; Wenzel C; Ball CR; Praetorius C; Schmidt T; Ringelband-Schilling B; Koschny R; Stenzinger A; Roeder I; Jaeger D; Zeissig S; Welsch T; Aust D; Glimm H; Folprecht G; Weitz J; Haag GM; Stange DE
    Mol Cancer; 2024 Jan; 23(1):10. PubMed ID: 38200602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
    Oshiro H; Tome Y; Kiyuna T; Yoon SN; Lwin TM; Han Q; Tan Y; Miyake K; Higuchi T; Sugisawa N; Katsuya Y; Park JH; Zang Z; Razmjooei S; Bouvet M; Clary B; Singh SR; Kanaya F; Nishida K; Hoffman RM
    Anticancer Res; 2019 Sep; 39(9):4667-4671. PubMed ID: 31519565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of human inspection and artificial intelligence-based morphological typing of patient-derived organoids reveals interpatient heterogeneity of colorectal cancer.
    Okamoto T; Natsume Y; Doi M; Nosato H; Iwaki T; Yamanaka H; Yamamoto M; Kawachi H; Noda T; Nagayama S; Sakanashi H; Yao R
    Cancer Sci; 2022 Aug; 113(8):2693-2703. PubMed ID: 35585758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxaliplatin and irinotecan induce heterogenous changes in the EMT markers of metastasizing colorectal carcinoma cells.
    Skarkova V; Kralova V; Krbal L; Matouskova P; Soukup J; Rudolf E
    Exp Cell Res; 2018 Aug; 369(2):295-303. PubMed ID: 29842879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
    Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
    Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
    Kim S; Choung S; Sun RX; Ung N; Hashemi N; Fong EJ; Lau R; Spiller E; Gasho J; Foo J; Mumenthaler SM
    SLAS Discov; 2020 Aug; 25(7):744-754. PubMed ID: 32349587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
    Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiproliferative Effects of Hop-derived Prenylflavonoids and Their Influence on the Efficacy of Oxaliplatine, 5-fluorouracil and Irinotecan in Human ColorectalC Cells.
    Ambrož M; Lněničková K; Matoušková P; Skálová L; Boušová I
    Nutrients; 2019 Apr; 11(4):. PubMed ID: 31010128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.